Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 3
1996 1
1997 2
1999 3
2001 5
2002 3
2003 6
2004 9
2005 14
2006 21
2007 15
2008 35
2009 40
2010 61
2011 63
2012 85
2013 94
2014 112
2015 153
2016 186
2017 207
2018 215
2019 219
2020 208
2021 204
2022 183
2023 149
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

2,121 results

Results by year

Filters applied: . Clear all
Page 1
Targeted Therapy and Immunotherapy in Melanoma.
Lazaroff J, Bolotin D. Lazaroff J, et al. Dermatol Clin. 2023 Jan;41(1):65-77. doi: 10.1016/j.det.2022.07.007. Epub 2022 Oct 28. Dermatol Clin. 2023. PMID: 36410984 Review.
While metastatic melanoma still carries significant mortality rates, the introduction of targeted therapy with BRAF/MEK inhibition and immunotherapy with PD-1, PD-L1, and CTLA-4 inhibitors has led to significant strides in outcomes and prognosis....
While metastatic melanoma still carries significant mortality rates, the introduction of targeted therapy with BRAF/MEK inhibition an …
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ, Flaherty KT, Ribas A, Long GV. Luke JJ, et al. Nat Rev Clin Oncol. 2017 Aug;14(8):463-482. doi: 10.1038/nrclinonc.2017.43. Epub 2017 Apr 4. Nat Rev Clin Oncol. 2017. PMID: 28374786 Free article. Review.
Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents. ...We summarize the state of the field and outline a rational approach …
Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the …
Immune checkpoint inhibitors in melanoma.
Carlino MS, Larkin J, Long GV. Carlino MS, et al. Lancet. 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. Lancet. 2021. PMID: 34509219 Review.
Despite the absence of adequately powered trial data, combined anti-CTLA4 and anti-PD-1 checkpoint inhibition has the highest 5-year overall survival rate of all therapies in advanced melanoma, and has high activity in melanoma brain metastases. ...PD-1 inhib …
Despite the absence of adequately powered trial data, combined anti-CTLA4 and anti-PD-1 checkpoint inhibition has the highest 5-year …
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). Garbe C, et al. Eur J Cancer. 2022 Jul;170:256-284. doi: 10.1016/j.ejca.2022.04.018. Epub 2022 May 24. Eur J Cancer. 2022. PMID: 35623961 Free article. Review.
Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness 1.0 mm or 0.8 mm with additional histological risk factors, although there is as yet no clear survival …
Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging proce …
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Hodi FS, et al. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or wit …
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 stud …
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Twyman-Saint Victor C, et al. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9. Nature. 2015. PMID: 25754329 Free PMC article.
Here we report major tumour regressions in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody (anti-CTLA4) and radiation, and reproduced this effect in mouse models. ...Thus, PD-L1 on melanoma cells allows tumours to esca …
Here we report major tumour regressions in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody ( …
Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma.
Liu D, Yang F, Zhang T, Mao R. Liu D, et al. J Transl Med. 2023 Jan 30;21(1):57. doi: 10.1186/s12967-023-03891-4. J Transl Med. 2023. PMID: 36717900 Free PMC article.
Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherapy are lacking. ...Prognosis, immunotherapeutic effect, tumor microenvironment score, expression of CD274, CTLA4, and PDCD1, and abund …
Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherap …
Single-cell analysis reveals new evolutionary complexity in uveal melanoma.
Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW. Durante MA, et al. Nat Commun. 2020 Jan 24;11(1):496. doi: 10.1038/s41467-019-14256-1. Nat Commun. 2020. PMID: 31980621 Free PMC article.
Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoint immunotherapy. ...Tumor-infiltrating immune cells comprise a previously unrecognized diversity of cell types, including CD8(+) T cells pr …
Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoi …
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM, Long GV. Menzies AM, et al. Eur J Cancer. 2013 Oct;49(15):3229-41. doi: 10.1016/j.ejca.2013.06.027. Epub 2013 Jul 16. Eur J Cancer. 2013. PMID: 23870385 Review.
Metastatic melanoma has a poor prognosis and until recently systemic therapy was ineffective. ...The first major advance was the development of selective mitogen-activated protein (MAP) kinase inhibitors (BRAF and MEK inhibitors) and immune checkpoint blockade with a CT …
Metastatic melanoma has a poor prognosis and until recently systemic therapy was ineffective. ...The first major advance was the deve …
Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.
Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Li J, et al. Clin Cancer Res. 2022 May 13;28(10):2131-2146. doi: 10.1158/1078-0432.CCR-21-3145. Clin Cancer Res. 2022. PMID: 35247927 Free PMC article.
PURPOSE: Acral melanoma is a rare subtype of melanoma that arises on the non-hair-bearing skin of the palms, soles, and nail beds. ...Acral melanoma was characterized by a lower overall immune infiltrate, fewer effector CD8 T cells and NK cells, and a near-co …
PURPOSE: Acral melanoma is a rare subtype of melanoma that arises on the non-hair-bearing skin of the palms, soles, and nail b …
2,121 results